F.O.C.U.S. in CML. Real-World Evidence (RWE) in Greece in patients with Chronic Myeloid Leukemia – Chronic Phase (CML-CP) who have already received at least one dose of Imatinib 600 mg following suboptimal response or failure to Imatinib 400 mg
Protocol No
FOCUS in CML v6
Trial information
Medical condition
CML
Trial phase
Phase 4
Sponsor
Vocate Pharmaceutical
Start date
02/11/2026
End date
30/11/2027
Main objective
Major Molecular Response (MMR, BCR::ABL1 ≤0.1% per IS) rate at 12 months from baseline, in patients for whom the treating physician has already decided on dose escalation.
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Ioannina
University General Hospital of Ioannina
Department of Hematology
Helen Kapsali
+30 26510 99655
Heraklion
University General Hospital of Heraklion
Charalampos Pontikoglou
+30 2810 392805
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.